Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pfizer europe ma eeig, belgicko - cytarabín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

actavis group ptc ehf., island - valsartan - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - valsartan - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - valsartan - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ever neuro pharma gmbh, rakúsko - apomorfín - 27 - antiparkinsonica

Európska únia - slovenčina - EMA (European Medicines Agency)

akcea therapeutics ireland limited - volanesorsen sodíka - hyperlipoproteinémia typu i - iných lipidov úprava agentov - waylivra je uvedené ako doplnok k strave dospelých pacientov s geneticky potvrdené, rodinné chylomicronemia syndróm (fcs) a na vysoké riziko pankreatitídy, v ktorých odpoveď na stravu a triglyceridov zníženie terapia bola neprimeraná.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pfizer europe ma eeig, belgicko - cytarabín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pfizer europe ma eeig, belgicko - cytarabín - 44 - cytostatica

Európska únia - slovenčina - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Európska únia - slovenčina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. Ďalšie informácie o stave receptora ľudského epidermálneho rastového faktora 2 (her2) nájdete v časti 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. Ďalšie informácie o stave her2 nájdete v časti 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).